Novel ruthenium and palladium complexes as potential anticancer molecules on SCLC and NSCLC cell lines

Basit Öğe Kaydı
dc.authoridAydemir, Murat/0000-0002-4238-5012
dc.authoridKARAGUR, Ege Riza/0000-0003-2189-8553
dc.contributor.authorTokgun, Onur
dc.contributor.authorKarakas, Duygu Elma
dc.contributor.authorTan, Semih
dc.contributor.authorKaragur, Ege Riza
dc.contributor.authorInal, Behcet
dc.contributor.authorAkca, Hakan
dc.contributor.authorDurap, Feyyaz
dc.date.accessioned2024-12-24T19:24:53Z
dc.date.available2024-12-24T19:24:53Z
dc.date.issued2020
dc.departmentSiirt Üniversitesi
dc.description.abstractLung cancer is one of the major causes of cancer-related deaths in the world. Non-small-cell lung cancer (NSCLC) is the most common type of lung cancer, and small-cell lung cancer (SCLC) is the most aggressive subtype of lung cancer. Proper therapies for SCLC have not yet been developed. However, new molecules have been designed and big innovation in treating SCLC has been achieved. Platinum-based antitumor drugs like cisplatin and carboplatin have several disadvantages including side effects, cisplatin-resistant tumors and limited solubility in aqueous media. Thus, two novel chiral aminoalcohol-based bis(phosphinite) ligands containing (eta(6)-p-cymene)-Ru(II)-phosphinite and bis(phosphinite)-Pd(II) complexes were synthesized and evaluated for anticancer activity. In this study, the results showed that complex1has the strongest cytotoxic effects on SCLC and NSCLC cell lines. On the other hand, cisplatin, ruthenium and palladium complexes are capable to induce apoptosis. Especially, complexes1and2can induce apoptosis for both SCLC and NSCLC. When compared to the qRT-PCR and TUNEL results, we obtained a significant correlation between apoptotic index and p21, Bax gene expressions. This work revealed the potential of the synthesized complexes as anticancer agents with cytotoxic and pro-apoptotic activity as leading compounds for further anticancer researches.
dc.identifier.doi10.1007/s11696-020-01129-x
dc.identifier.endpage2892
dc.identifier.issn2585-7290
dc.identifier.issn1336-9075
dc.identifier.issue9
dc.identifier.scopus2-s2.0-85081330981
dc.identifier.scopusqualityQ2
dc.identifier.startpage2883
dc.identifier.urihttps://doi.org/10.1007/s11696-020-01129-x
dc.identifier.urihttps://hdl.handle.net/20.500.12604/6175
dc.identifier.volume74
dc.identifier.wosWOS:000540601300014
dc.identifier.wosqualityQ3
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.language.isoen
dc.publisherSpringer International Publishing Ag
dc.relation.ispartofChemical Papers
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.snmzKA_20241222
dc.subjectSCLC
dc.subjectNSCLC
dc.subjectPhosphinite
dc.subjectPalladium
dc.subjectRuthenium
dc.subjectp21
dc.subjectBax
dc.titleNovel ruthenium and palladium complexes as potential anticancer molecules on SCLC and NSCLC cell lines
dc.typeArticle

Dosyalar

Koleksiyon

WOS İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu